How common is it for sertraline and low‑dose aspirin (acetylsalicylic acid) to cause epistaxis or bleeding?

How Common Are Nosebleeds and Bleeding with Sertraline and Baby Aspirin?

The combination of sertraline and low-dose aspirin significantly increases bleeding risk, with aspirin causing epistaxis in approximately 30% of emergency epistaxis cases and SSRIs like sertraline roughly doubling gastrointestinal bleeding risk when combined with aspirin or NSAIDs. 1, 2, 3

Aspirin-Related Bleeding Frequency

Low-dose aspirin alone increases epistaxis risk approximately 9-fold compared to patients not taking antiplatelet agents 4. In emergency department epistaxis presentations:

• Nearly 30% of all epistaxis patients presenting to emergency departments are taking aspirin 2
• Aspirin users show significantly more surgical interventions, higher recurrence rates, and increased severity scores for nosebleeds 2
• Every single patient requiring surgical intervention for recurrent epistaxis in one long-term study was taking aspirin 5
• The relative risk of troublesome epistaxis requiring medical attention is increased 9-fold (RR = 9.04,95% CI = 5.13-15.96) with low-dose aspirin 4

For gastrointestinal bleeding specifically:

• Low-dose aspirin (75-325 mg/day) increases GI bleeding risk 2-4 times baseline 6
• In patients with prior MI, aspirin causes only 1-2 major GI bleeding events per 1,000 patients per year while preventing 20 major vascular events 7
• Aspirin-related upper GI bleeding carries a 5-10% mortality rate, though the absolute excess is only 1% of prevented vascular events 7

Sertraline-Related Bleeding Frequency

The FDA label for sertraline explicitly warns that SSRIs may increase bleeding risk ranging from epistaxis and ecchymoses to life-threatening hemorrhage 1. Specific data:

• Concomitant use of sertraline with aspirin or NSAIDs significantly increases bleeding risk beyond either agent alone 1
• Case reports document acquired platelet function defects during sertraline exposure contributing to recurrent epistaxis 8
• The FDA label states that "concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants or other drugs known to affect platelet function may add to this risk" 1

Combined Sertraline Plus Aspirin Risk

When SSRIs are combined with NSAIDs or aspirin, the risk of GI bleeding more than doubles 3:

• Network meta-analysis shows SSRI/NSAID combination increases GI bleeding odds 2.14-fold compared to SSRI alone (OR 2.14,95% CI 1.52-3.02) 3
• SSRI/NSAID combination increases bleeding 1.49-fold compared to NSAID alone (OR 1.49,95% CI 1.20-1.84) 3
• The combination of NSAIDs and aspirin increases relative GI bleeding risk more than 10-fold compared to either agent alone 6

Clinical Context and Risk Stratification

Aspirin intake is identified as the most common risk factor in bleeding peptic ulcers, found in 53% of cases 6. For epistaxis specifically:

• Aspirin use (53% of cases) and hypertension (68% of cases) are the leading causes of emergency department epistaxis admissions in adults 9
• Inherited coagulopathies are rare (only 5% in one study), making medication history far more clinically relevant 9
• In long-term follow-up, aspirin intake is a risk factor for severity of recurrent epistaxis requiring surgical intervention 5

Critical Clinical Pitfalls

The bleeding risk is real and clinically significant, but must be weighed against cardiovascular benefit 7:

• Do not reflexively discontinue aspirin for non-life-threatening epistaxis, as cardiovascular risks often outweigh bleeding risks 7
• Enteric-coated, buffered, and plain aspirin have essentially equivalent bleeding risks (RR 2.6,2.7, and 3.1 respectively at 325 mg daily) 6
• Patients should be explicitly counseled about bleeding risk when prescribing sertraline to those already on aspirin 1
• Consider proton pump inhibitor prophylaxis for patients on both sertraline and aspirin, particularly if age >60 years or other GI risk factors present 6

Management When Bleeding Occurs

Prioritize aggressive local hemostatic measures over medication discontinuation 7:

• Firm sustained nasal compression for 5-15 minutes controls 65-75% of epistaxis cases 7
• Topical vasoconstrictors and nasal cautery are first-line interventions 7
• Do not routinely discontinue aspirin for non-life-threatening epistaxis 7
• Do not routinely transfuse platelets unless bleeding is life-threatening or persists despite all local measures 7